Skip to main content
. 2013 Apr;57(4):1701–1708. doi: 10.1128/AAC.00934-12

Fig 3.

Fig 3

The novel 3NI analog greatly reduces HSV-1 infectivity. The antiviral activities of wild-type hBD1 and hBD3 and the analogs 1C, 3I, 3N, and 3NI were tested against HSV-1 at a concentration of 20.0 μM. Error bars show the SDs from three independent experiments.